PuSH - Publikationsserver des Helmholtz Zentrums München: Heterozygous <em>STAT1</em> gain-of-function mutations underlie an unexpectedly broad clinical phenotype: An international survey of 274 patients from 167 kindreds.

Informationen

Hinweise zu Qualitätskriterien von Zeitschriften

Open-Access-Richtlinie der Helmholtz-Gemeinschaft 2016

CC Licencences

Metriken für Publikationen

Navigation

Startseite

English

EVA: Veröffentlichen

Neuer EVA Antrag

Recherche

Erweiterte Suche

Durchblättern nach ...

... HMGU-Autoren/Konsortien

... Organisationsstruktur

... Zeitschriften

... Publikationstypen

... Forschungsdaten

... Arbeitsgruppen

... Erscheinungsjahr

Publikationen im Überblick

Statistik

HGF Fortschrittsbericht

OA Publikationen

Eintragen

Neue Publikation eintragen

Neue Publikation holen aus...

...EVA

Fehlende Publikation melden

Highlights

Suche

Hilfe & Kontakt

Ansprechpartner

Hilfe

Datenschutz

Helmholtz Open Science

Bibliometrische Indikatoren

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Toubiana, J.* ; Okada, S.* ; Hiller, J. ; Oleastro, M.* ; Lagos Gomez, M.* ; Aldave Becerra, J.C.* ; Ouachée-Chardin, M.* ; Fouyssac, F.* ; Girisha, K.M.* ; Etzioni, A.* ; van Montfrans, J.* ; Camcioglu, Y.* ; Kerns, L.A.* ; Belohradsky, B.* ; Blanche, S.* ; Bousfiha, A.* ; Rodriguez-Gallego, C.* ; Meyts, I.* ; Kisand, K.* ; Reichenbach, J.* ; Renner, E.D.* ; Rosenzweig, S.* ; Grimbacher, B.* ; van de Veerdonk, F.L.* ; Traidl-Hoffmann, C. ; Picard, C.* ; Maródi, L.* ; Morio, T.* ; Kobayashi, M.* ; Lilic, D.* ; Milner, J.D.* ; Holland, S.* ; Casanova, J.L.* ; Puel, A.*

Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype: An international survey of 274 patients from 167 kindreds.

Blood 127, 3154-3164 (2016)

Verlagsversion

Postprint

DOI

PMC

	Open Access Green

Abstract
Metriken
Zusatzinfos

Since their discovery in patients with autosomal dominant (AD) chronic mucocutaneous candidiasis (CMC) in 2011, heterozygous STAT1 gain-of-function (GOF) mutations have increasingly been identified worldwide. The clinical spectrum associated with them needed to be delineated. We enrolled 274 patients from 167 kindreds originating from 40 countries from five continents. Demographic data, clinical features, immunological parameters, treatment, and outcome were recorded. The median age of the 274 patients was 22 years (range: 1 - 71 years); 98% of them had CMC, with a median age at onset of one year (range: 0 - 24 years). Patients often displayed bacterial (74%) infections, mostly due to Staphylococcus aureus (36%), including the respiratory tract and the skin in 47% and 28% of patients, respectively, and viral (38%) infections, mostly due to Herpesviridae (83%) and affecting the skin in 32% of patients. Invasive fungal infections (10%), mostly caused by Candida spp. (29%), and mycobacterial disease (6%) caused by Mycobacterium tuberculosis, environmental mycobacteria, or BCG vaccines, were less common. Many patients had autoimmune manifestations (37%), including hypothyroidism (22%), type 1 diabetes (4%), blood cytopenia (4%), and systemic lupus erythematosus (2%). Invasive infections (25%), cerebral aneurysms (6%), and cancers (6%) were the strongest predictors of poor outcome. CMC persisted in 39% of the 202 patients receiving prolonged antifungal treatment. Circulating IL-17A-producing T-cell count was low for most (82%) but not all of the patients tested. STAT1 GOF mutations underlie AD CMC, as well as an unexpectedly wide range of other clinical features, including not only a variety of infectious and autoimmune diseases, but also cerebral aneurysms and carcinomas that confer a poor prognosis.

Impact Factor

Scopus SNIP

Web of Science
Times Cited

Scopus
Cited By

Altmetric

11.841

2.502

265

318